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Two major pathways contribute to Ras-
proximate-1–mediated integrin activation
in stimulated platelets. Calcium and dia-
cyglycerol-regulated guanine nucleotide
exchange factor I (CalDAG-GEFI, Ras-
GRP2) mediates the rapid but reversible
activation of integrin IIb3, while the
adenosine diphosphate receptor P2Y12,
the target for antiplatelet drugs like clopi-
dogrel, facilitates delayed but sustained
integrin activation. To establish CalDAG-
GEFI as a target for antiplatelet therapy,
we compared how each pathway contrib-
utes to thrombosis and hemostasis in
mice. Ex vivo, thrombus formation at arte-
rial or venous shear rates was markedly
reduced in CalDAG-GEFI/ blood, even
in the presence of exogenous adenosine
diphosphate and thromboxane A2. In vivo,
thrombosis was virtually abolished in ar-
terioles and arteries of CalDAG-GEFI/
mice, while small, hemostatically active
thrombi formed in venules. Specific dele-
tion of the C1-like domain of CalDAG-
GEFI in circulating platelets also led to
protection from thrombus formation at
arterial flow conditions, while it only mar-
ginally increased blood loss in mice. In
comparison, thrombi in the micro- and
macrovasculature of clopidogrel-treated
wild-type mice grew rapidly and fre-
quently embolized but were hemostati-
cally inactive. Together, these data sug-
gest that inhibition of the catalytic or the
C1 regulatory domain in CalDAG-GEFI
will provide strong protection from athero-
thrombotic complications while maintain-
ing a better safety profile than P2Y12
inhibitors like clopidogrel. (Blood. 2011;
117(3):1005-1013)
Introduction
Arterial thrombosis in the coronary or cerebrovascular circulation
is the principal pathological process underlying acute coronary
syndrome and ischemic stroke, which together represent the
leading cause of morbidity and mortality in industrialized coun-
tries.1 Platelet activation is a central event in the pathogenesis of
arterial thrombosis. Currently, the most powerful antiplatelet
agents used in the clinic are inhibitors of cyclooxygenase-1
(acetylsalicylic acid, aspirin), the platelet adenosine diphosphate
(ADP) receptor P2Y12 (eg, clopiodgrel or Plavix), and integrin
IIb3 (eg, abciximab or Reopro).2,3 These agents have all been
shown to improve clinical outcomes in large-scale randomized
controlled trials. However, all therapies have limitations that
include uncertainty about optimal dosing, questions about resis-
tance, and issues regarding the lack of reversibility in situations
where bleeding risks are high.
IIb3, the platelet fibrinogen receptor, is the best-studied
member of the integrin family.4,5 Like most integrins, especially
those regulating adhesion and trafficking of blood cells, it is
expressed in a low-affinity state on resting platelets. Engagement of
agonist receptors on the platelet surface triggers intracellular
signaling events, which lead to inside-out activation of IIb3.
Deficiency in IIb3 completely inhibits the ability of platelets to
aggregate and adhere to sites of injury.6,7 Consequently, inhibitors
to integrin IIb3 show the strongest protection from thrombotic
complications, but they also markedly increase the risk of fatal
bleeding complications. In contrast, inhibitors to P2Y12 reduce but
do not abolish platelet function. P2Y12 signaling is evoked when
ADP is released from dense granules of activated platelets. In a
growing thrombus, ADP is important for the amplification of the
initial activation of adherent platelets as well as the recruitment of
circulating platelets to the thrombus surface.8 Consequently, ge-
netic knockout9 or inhibition10 of P2Y12 in mice led to the
formation of unstable thrombi and continuous bleeding in the
mouse tail bleed assay.
We recently established a simplified model for platelet activa-
tion in which 2 signaling pathways control the activation of the
small GTPase Ras-proximate-1 (Rap1).11,12 Activation of phospho-
lipase C, an event common to the signaling induced by all
physiological agonists, leads to the generation of the second
messengers calcium (Ca2) and diacylglycerol (DAG). An increase
in the intracellular Ca2 concentration triggers the activation of
calcium and diacyglycerol-regulated guanine nucleotide exchange
factor I (CalDAG-GEFI, RasGRP2), a GEF that directly activates
Rap1.13-15 In addition to the GEF domain, CalDAG-GEFI contains
a pair of Ca2 binding EF hand domains and a C1-like domain with
hitherto unknown function.16 DAG is a well-established activator
of protein kinase C (PKC) and therefore granule release in platelets.17,18
PKC-dependent integrin activation depends on positive feedback
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by the Gi-coupled P2Y12 receptor,19 which again leads to the
activation of Rap1.11,12,20 Importantly, CalDAG-GEFI–mediated
Rap1 activation is rapid but reversible, while P2Y12-mediated
Rap1 activation occurs with a delay but is more stable. Thus,
2 kinetically distinct pathways converge at the level of Rap1, a
molecular switch that drives platelet activation by triggering
integrin activation, thromboxane A2 (TxA2) generation, and gran-
ule release.12,21
Our recent work suggested CalDAG-GEFI as a potential new
target for antiplatelet therapy, as it (i) is the major signal integrator
for Ca2 in platelets, (ii) plays a crucial role in the near-immediate
activation of platelets, and (iii) provides feedback to but is not
required for signaling via the PKC/P2Y12-dependent pathway.
Furthermore, its complex domain structure may allow targeting of
a regulatory rather than the catalytic domain within CalDAG-
GEFI. To validate CalDAG-GEFI as a new target for antiplatelet
therapy, and to determine the mechanism(s) by which the CalDAG-
GEFI/Rap1 signaling module contributes to thrombus formation
under physiological flow conditions, we subjected CalDAG-
GEFI/ and clopidogrel-treated wild-type (WT) mice to several
state-of-the-art mouse models of thrombosis and hemostasis. Our
studies identify CalDAG-GEFI signaling as a crucial component of
the initial phase of platelet adhesion and thrombus formation,
particularly under arterial shear conditions. Inhibition of P2Y12,
however, led to thrombus instability but had little effect on the
initial thrombus growth. In addition, we observed that CalDAG-
GEFI deficiency has less impact on hemostasis in mice than P2Y12
inhibition. Thus, our studies indicate that targeting the initial phase
of integrin activation mediated by CalDAG-GEFI may be superior
to blocking sustained IIb3 activation as achieved by inhibitors
of P2Y12. Furthermore, we provide the first evidence that the C1
domain is critical for CalDAG-GEFI function and that inactivation
of this regulatory domain may provide a mechanism to further
improve the safety of anti-CalDAG–GEFI therapy.
Methods
For information on materials, Western blotting, immunofluorescence, and
aggregometry, see supplemental information (available on the Blood Web
site; see the Supplemental Materials link at the top of the online article).
Mice
CalDAG-GEFI/14 and littermate control WT mice were bred in the
mouse facility of Thomas Jefferson University. Where indicated, WT or
CalDAG-GEFI/ mice were treated with clopidogrel 24 and 3 hours
before the experiment at a dosage of 75 mg/kg bodyweight. P2Y12
inhibition was confirmed by standard aggregometry (impaired response to
ADP, not shown). Treatment with clopidogrel did not affect platelet counts
or counts of other blood cells (data not shown). Experimental procedures
were approved by the Animal Care and Use Committee of Thomas
Jefferson University.
Generation of chimeric mice expressing CalDAG-GEFIC1 in
blood cells only
Retrovirus construction The cDNA of murine CalDAG-GEFI was kindly
provided by Drs Jill Crittenden and Ann Graybiel (Massachusetts Institute
of Technology, Cambridge, MA). The C1 deletion mutant was generated
using overlap polymerase chain reaction. Primers used were as follows: C1
deletion forward 5-GAGGCCGCATGGGATTCGTA. CGTCGCAGAGCT-
CAGAGTGTCA; C1 deletion reverse 5–TGACACTCTGAGCTCTGC-
GACG.TACGAATCCCATGCGGCCTC. WT and mutant cDNAs were
subcloned into the murine stem cell virus MigR1 viral vector with an
internal ribosome entry site-green fluorescent protein (IRES-GFP) inserted
before the polyadenylation signal as previously described (kindly provided
by Mark Kahn, University of Pennsylvania).22
Bone marrow cell transplantation Bone marrow cells were harvested
from the tibia and femur of adult CalDAG-GEFI/ mice, cultured
overnight in Iscove modified Dulbecco medium with a supplement of
murine stem cell factor, interleukin-3, and interleukin-6. The cells were
transduced twice by spinfection (50) at 1000g with retrovirus at a
multiplicity of infection equal to 5 virions per cell. The transduction
efficiency after the second spinfection was 20% to 50%. A total of 2  106
cells were transplanted by retro-orbital injection (100 L per mouse) into
recipient animals (8-10 weeks old) conditioned with a lethal dose of
2  600 cGy total body irradiation. Six to eight weeks after transplantation,
bone marrow was harvested and sorted for GFP positivity at the Thomas
Jefferson University flow cytometry core facility, followed by transplanta-
tion of GFP-positive bone marrow cells into another set of lethally
irradiated recipient mice (CalDAG-GEFI/). Some of the GFP-expressing
WT chimeric mice were generated by transplant of bone marrow cells
isolated from C57Bl/6 mice transgenic for GFP (The Jackson Laboratory).
The platelet counts in all chimeric mice recovered to levels  70% of WT
controls within 6 to 8 weeks after transplant.
Platelet preparation
Blood was drawn from the retro-orbital plexus into heparinized tubes.
Platelet-rich plasma was obtained by centrifugation at 100g for 5 minutes.
Platelet-rich plasma was centrifuged at 700g in the presence of PGI2
(2 g/mL) for 5 minutes at room temperature. After 2 washing steps,
pelleted platelets were resuspended at the concentration of 4  108
platelets/mL in modified Tyrode Buffer (137mM NaCl, 0.3mM Na2HPO4,
2mM KCl, 12mM NaHCO3, 5mM N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid, 5mM glucose, pH 7.3) containing 0.35% bovine serum
albumin and 1mM CaCl2.
Flow cytometry
GFP expression in blood platelets Heparin-anticoagulated whole blood
from WT control and CalDAG-GEFI	C1 chimeric mice was diluted in
phosphate-buffered saline (PBS) and analyzed on a FACScan (BD
Biosciences).
IIb3 activation Washed platelets were diluted in Tyrode buffer
containing 1mM CaCl2, activated with convulxin or PAR4-activating
peptide (PAR4p) in the presence of R-phycoerythrin-conjugated JON/A
antibody (JON/A-PE)23 for 10 minutes and studied immediately by flow
cytometry. In studies with CalDAG-GEFI	C1 platelets, 2-MesAMP
(2-methylthioadenosine 5-monophosphate triethylammonium salt; 75M)
was added before platelet stimulation to eliminate feedback by P2Y12
receptor signaling.
Flow chamber studies In vitro flow studies were performed in a
microfluidic device fabricated in poly dimethylsiloxane. Fabrication of
microfluidic devices and microfluidic collagen patterning were performed
as previously described.24 Briefly, a 100-m strip of fibrillar collagen type I
(200 g/mL) was deposited and immobilized by microfluidic patterning
along the length of a glass slide. A poly dimethylsiloxane device with
10 flow channels (width: 250 m, height: 60 m, length: 6 mm) was
oriented perpendicularly to the patterned collagen. Murine whole blood was
drawn from the retro-orbital plexus into heparinized tubes (30 U/mL
Lovenox), incubated with 1.5 g/mL of anti-GPIX (glycoprotein IX)–
Alexa488 and infused at arterial (2000S) or venous (400S) wall shear
rates for 5 minutes. In some experiments, ADP and the TxA2 analog,
U46619, were added to CalDAG-GEFI/ whole blood immediately before
the beginning of the perfusion. Adhesion of platelets was monitored
continuously with a Nikon Ti-U inverted microscope (Nikon Instruments Inc)
equipped with a Retiga EXL monochrome camera (QImaging; objective lenses,
Plan fluor (air) 20/0.45). Images were analyzed using Nikon NIS
Elements Version 3.0 software (NIS-Elements Advanced Research).
Platelet depletion Mice were injected retro-orbitally with a commer-
cially available antibody to mouse GPIb.25 Successful platelet depletion
(peripheral platelet counts 
 2% of untreated control mice) was confirmed
by flow cytometry 1 hour after infusion of anti-GPIb antibody.
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Tail bleeding time and estimated blood loss measurement Mice
(approximately 8 weeks old) were matched for weight and anesthetized
with 100 mg/kg ketamine (Forte Dodge Animal Health) and 10 mg/kg
xylazine (Lloyd Laboratories) 10 minutes before tail transection. Mice were
placed on a heating pad, and tails were transected 2 mm from the tip with a
razor blade and immediately immersed into a 20-mL scintillation vial filled
with 5 mL PBS (37°C). The time to cessation of bleeding was recorded, and
after 10 minutes the bleeding was stopped by cauterization. To measure
blood loss volume, the collected blood sample was frozen at 80°C
overnight, thawed, and 5 mL of red blood cell lysis buffer (155mM NH4Cl,
10mM KHCO3, 0.1mM Na2 EDTA [disodium ethylenediamine tetraac-
etate[, pH  7.3) was added. The optical density (490) was determined and
compared with a standard curve. Statistical significance for the blood loss
volume was determined by Mann-Whitney test.
Laser injury in the cremaster muscle The studies on laser-induced
thrombosis in the cremaster muscle were performed as previously de-
scribed.26 Briefly, male mice (12-14 weeks of age) were anesthetized with
pentobarbital (11 mg/kg; Abbott Laboratories), and platelet adhesion was
studied in arterioles and venules of the cremaster muscle (10-20 m) using
an Olympus BX61WI microscope (Olympus) with a 40/0.8 numeric
aperture water-immersion objective lens. Laser injuries were done using an
SRS NL100 Nitrogen Laser system (Photonic Instruments) at 65% energy
level. Injuries were initiated 5 minutes after the intravenous injection of
Alexa488-coupled Fab fragments of MWReg30, an antibody directed
against murine IIb3 (0.2 g/g body weight, BD Pharmingen). Data were
collected over 3 minutes at 5 frames/s and then averaged at each time point.
Videos were analyzed using Slidebook Version 5.0.0.17 software
(Intelligent-Imaging-Solutions).
FeCl3-induced thrombosis in mesenteric venules. Three- to 5-week-
old anesthetized male mice were retro-orbitally injected with Alexa488-
conjugated antibodies to GPIX (0.1 g/g, labeling of circulating platelets)
or JON/A-PE (0.15 g/g, labeling of activated IIb3). The mesentery was
exposed through a midline abdominal incision. Arterioles and venules were
examined with a Nikon Eclipse Ti-U inverted microscope (Nikon) equipped
with a Retiga EXL monochrome camera (QImaging; objective lenses, Plan
fluor (air) 20/0.45 and Plan Apo 10/0.45). Vessel injury was generated
by placing a filter paper (1  4 mm) soaked with 10% FeCl3 on the vessel
for 3.5 minutes. The filter paper was then removed, and the vessel was
superfused with saline. Vessels were monitored for 40 minutes after FeCl3
treatment or until blood flow stopped for longer than 10 seconds (identified
as occlusion time). Videos were analyzed using Nikon NIS Elements
Version 3.0 software (NIS-Elements, Advanced Research).
FeCl3-induced thrombosis in the carotid artery. The right carotid
artery of an anesthetized adult mouse (6-10 weeks of age, 100 mg
pentobarbital per kg body weight) was exposed to a strip of filter paper
saturated with FeCl3 (10% for 4 minutes or 40% for 2.5 minutes), then
rinsed with PBS. Arterial flow rate was recorded for 30 minutes with a
Doppler flow probe (Transonic). Stable occlusive thrombi were scored as
complete cessation of blood flow, which remained for the 30-minute
duration of the assay. Thrombi were scored as unstable if flow resumed
before the end of the 30-minute time period or if the flow rate changed
repeatedly by  30% compared with the initial flow rate. The animal was
scored as having no detectable thrombus if the flow rate never decreased by
 30% of the initial flow rate during the term of the assay. The mice were
killed at the end of the procedure.
Statistical analysis Results are reported as mean SEM, and statistical
significance was assessed by unpaired 2-tailed Student t test, unless
otherwise indicated. A P value less than .05 was considered significant.
Results
Thrombotic profile of CalDAG-GEFI/ and clopidogrel-treated
WT mice
We first performed flow chamber studies to determine the shear
dependency of CalDAG-GEFI– and P2Y12-mediated thrombus
formation on a collagen surface (Figure 1A and supplemental
Videos 1-4). Platelets in whole blood were labeled with an
Alexa488-conjugated antibody to GPIX, and fluorescence accumu-
lation on the collagen surface was used to quantify the adhesion
process. Compared with controls, thrombus formation at arterial
shear rates (2000 s1, Figure 1A left panel) was completely
abolished in blood isolated from both CalDAG-GEFI/ and
clopidogrel-treated WT mice (WT/clopidogrel). In both cases,
firmly adherent platelets were observed on the collagen surface at
the end of the perfusion period (not shown). Under venous shear
conditions (400 s1, Figure 1A right panel), WT/clopidogrel
platelets formed 3-dimensional thrombi (supplemental Video 2).
However, thrombi were unstable and frequently embolized, result-
ing in a significant reduction in platelet coverage of the collagen
surface compared with WT controls (supplemental Video 1). In
contrast, CalDAG-GEFI/ platelets were not able to form thrombi
on the collagen surface (supplemental Video 3) but eventually
formed a monolayer of firmly adherent cells similar to that
observed in WT/clopidogrel blood at the end of the perfusion
period. Clopidogrel treatment of CalDAG-GEFI/ mice further
reduced platelet adhesion to collagen (supplemental Video 4),
confirming the importance of both pathways for integrin-mediated
platelet adhesion. These studies demonstrate that, although both
CalDAG-GEFI/ and WT/clopidogrel platelets can form stable
aggregates in a standard aggregometry assay, both pathways have
to be active to enable formation of stable thrombi under flow
conditions on collagen.
We recently demonstrated that CalDAG-GEFI is central to
various aspects of Ca2-dependent platelet activation such as
integrin activation, TxA2 generation, and granule release.11,12 To
establish if impaired release of second wave mediators contributes
to the adhesion defect observed in CalDAG-GEFI/ platelets, we
co-infused ADP and the TxA2 analog, U46619, with CalDAG-
GEFI/ blood. At both arterial and venous shear rates, we
observed that co-infusion of ADP and U46619 led to a marked
increase in the surface area covered by fluorescent platelets (Figure
1B top panel, and Figure 1C). In contrast, only a small increase in
the overall fluorescence on the collagen strip was detected (Figure
1B bottom panel, and Figure 1C), suggesting that the addition of
exogenous mediators increased the adhesion of single platelets to
the collagen surface while it did not restore 3-dimensional throm-
bus growth.
A limitation of the flow chamber assay is that it is performed
with anticoagulated blood; that is, it does not account for the
generation of thrombin, which is a central component of the
thrombogenic response in vivo. Our previous in vitro studies,
however, demonstrated that CalDAG-GEFI/ platelets respond
better to thrombin than to collagen.11,12,14 To investigate whether
CalDAG-GEFI deficiency also protects from thrombin-driven
thrombosis, we studied thrombus formation at a site of vascular
injury, both in arterioles and venules (Figure 2 and supplemental
Videos 5-8). As previously shown, laser-induced thrombosis in the
cremaster microcirculation represents a model of localized, throm-
bin-driven thrombosis.27,28 When subjected to this model, CalDAG-
GEFI/ mice showed decreased platelet accumulation compared
with WT mice in both arterioles (Figure 2A-B) and to a lesser
extent in venules (Figure 2D-E). Thrombi in venules of CalDAG-
GEFI/ mice grew slowly but remained stably anchored to the
vessel wall. Treatment of WT mice with clopidogrel significantly
reduced thrombus size in arterioles and venules. Initial thrombus growth
under these conditions occurred with similar kinetics as in WT controls,
but thrombi were unstable and frequently embolized (Figure 2C,F).
Platelet adhesion was almost completely inhibited in venules and
arterioles of clopidogrel-treated CalDAG-GEFI/ mice.
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Similar results were obtained in a second microvascular throm-
bosis model, ferric chloride (FeCl3)–induced thrombosis in the
mesentery. Compared with laser injury, FeCl3 induces a more
severe injury to the endothelium, resulting in exposure of subendo-
thelial collagen and the generation of thrombin.29 In WT animals,
occlusive thrombi formed in arterioles (not shown) and venules
within 9-15 minutes after FeCl3 application (Figure 3A left panel,
and Figure 3C). Clopidogrel-treated WT animals were protected
from vessel occlusion (Figure 3C), but thrombi of considerable size
(up to 70 m in diameter) formed in both arterioles (not shown)
and venules (Figure 3A middle panel). Thrombi in clopidogrel-
treated mice grew rapidly but embolized more frequently through-
out the entire observation period (Figure 3D-E). The emboli stained
positive for activated IIb3 (Figure 3B), excluding the possibility
that they consisted of passively agglutinated, nonactivated plate-
lets. In contrast, small but stable mural thrombi formed with a delay
in venules (Figure 3A right panel, and Figure 3D) of CalDAG-
GEFI/ animals, while thrombus formation was not observed
in injured arterioles.30 As observed in the laser injury model,
thrombus formation was completely inhibited in FeCl3-injured
arterioles and venules of clopidogrel-treated CalDAG-GEFI/
mice (not shown).
To validate our findings in a macrovascular thrombosis model,
we studied the thrombotic response of CalDAG-GEFI/ and
WT/clopidogrel mice in FeCl3-injured carotid arteries. Thrombus
formation in the carotid artery was detected by a reduction in the
blood flow rate. Compared with WT controls, both study groups
were completely protected from the formation of occlusive thrombi,
both under mild (10% FeCl3) and severe (40% FeCl3) injury
conditions (Figure 4A). Upon mild injury, no marked reduction in
blood flow occurred in either CalDAG-GEFI/ or clopidogrel-
treated WT mice, although occlusive thrombi formed in all
untreated WT mice. Upon severe injury, however, unstable thrombi
were observed in 40% of the WT/clopidogrel mice but not in
CalDAG-GEFI/ mice. Characteristic flow traces showing stable
occlusion in a WT mouse, unstable thrombus formation in a
WT/clopidogrel mouse, and protection from thrombosis in a
CalDAG-GEFI/ mouse are shown in Figure 4B.
Role of CalDAG-GEFI and P2Y12 in hemostasis in mice
An increased risk of bleeding is the most serious side effect of
antiplatelet agents like clopidogrel. To assess the bleeding tendency
in mice, we subjected CalDAG-GEFI/ and clopidogrel-treated
WT mice to a tail-bleeding assay, and we compared their bleeding
phenotype to that of thrombocytopenic mice (antibody-induced
depletion of more than 98% of circulating platelets; Figure 5). The
majority of clopidogrel-treated WT mice (20/20), CalDAG-
GEFI/ mice (22/25), and platelet-depleted WT mice (6/6) bled
for the entire observation period (Figure 5A). To more quantita-
tively evaluate the bleeding risk in the various groups, we
determined the amount of blood lost from the severed vessels
(Figure 5B). Animals in all study groups lost significantly more
blood than WT control mice. However, CalDAG-GEFI/ mice
lost significantly less blood than platelet-depleted or clopidogrel-
treated WT mice, suggesting that signaling via P2Y12 supports the
Figure 1. Platelet adhesion to fibrillar collagen under physiological flow conditions. (A) Whole blood from WT (WT, black lines and bars), CalDAG-GEFI/ (knockout
[KO], red), clopidogrel-treated WT (WT  clop., blue), or clopidogrel-treated KO (KO  clop., green) mice was perfused over collagen at arterial (2000 s1, left) or venous (400
s1, right) shear conditions. Platelets in whole blood were labeled with Alexa488-labeled antibodies to GPIX before perfusion. The top graphs represent time traces of the mean
fluorescence intensity SEM expressed as a percentage of the maximal fluorescence observed (WT blood, 400 s1). The bar graphs show the area coverage by fluorescent
platelets after 5 minutes of blood perfusion, expressed as percentage of the collagen-coated area. Data are shown as mean  SEM (n  4-6, 3 independent experiments).
*P 
 .05, **P 
 .01, ***P 
 .001. See supplemental Videos 1 to 4 for a better visualization of the differences in thrombus growth and stability observed in the respective study
groups. (B-C) Effect of exogenous ADP and TxA2 (U46619) on the adhesion of CalDAG-GEFI/ platelets. WT and CalDAG-GEFI/ (KO) whole blood was perfused over
collagen at 400 s1 or 2000 s1 in the presence (KO  ADP/U46) or absence (KO) of exogenous ADP (25M) and U46619 (5M). (B) Bar graphs for area coverage (top) and
fluorescence intensity (bottom) measured after 5 minutes of perfusion with the following blood samples: WT (black bar), KO (red bar), and KO reconstituted with 25M ADP and
5M U46619 (KO  ADP/U46, red checkered bar). Data are shown as mean  SEM (n  5, 3 independent experiments). *P 
 .05; **P 
 .01; ***P 
 .001.
(C) Representative images. Images were obtained after 5 minutes of perfusion on a Nikon Eclipse Ti-U inverted microscope (equipped with a Retiga EXL monochrome camera
[QImaging] and Nikon NIS Elements software [NIS-Elements Advanced Research]).
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formation of hemostatically functional thrombi. In contrast, no
significant difference in blood loss was observed between clopi-
dogrel-treated and platelet-depleted WT mice.
Role of the regulatory C1 domain for CalDAG-GEFI function
As part of ongoing structure-function studies on CalDAG-GEFI,
we generated chimeric mice expressing CalDAG-GEFI that lacks
the C1 regulatory domain (CalDAG-GEFI	C1) in circulating
blood cells. Chimeric mice were generated by retroviral transduc-
tion of bone marrow cells and subsequent transplant of the
transduced cells into lethally irradiated mice. As evaluated by flow
cytometry,  95% of circulating platelets in the chimeric mice
(both WT/GFP, expressing intact CalDAG-GEFI, and 	C1/GFP,
expressing CalDAG-GEFI	C1) showed similar levels of GFP
(Figure 6A) and stained positive for CalDAG-GEFI (not shown).
Compared with WT controls, CalDAG-GEFI	C1 platelets ex-
pressed a lower molecular weight CalDAG-GEFI protein, confirm-
ing the deletion of the C1 domain in these platelets (Figure 6B).
Immunofluorescence studies demonstrated cytosolic expression for
both CalDAG-GEFI	C1 and intact CalDAG-GEFI in resting
platelets (Figure 6C). To evaluate the ability of CalDAG-GEFI	C1
to support IIb3 activation in platelets, we studied JON/A-PE23
binding to WT, CalDAG-GEFI/, CalDAG-GEFI/, and
CalDAG-GEFI	C1 platelets stimulated in the presence of the
P2Y12 inhibitor, 2-MesAMP. IIb3 activation in CalDAG-
GEFI	C1 platelets was significantly stronger than in CalDAG-
GEFI/ platelets but weaker than that observed in CalDAG-
GEFI/ platelets (ie, in platelets with a 50% reduction in
CalDAG-GEFI expression; Figure 6D). CalDAG-GEFI–dependent
IIb3 activation in CalDAG-GEFI	C1 platelets activated via the
thrombin receptor PAR4 (PAR4p) or the collagen receptor glycop-
rotein VI (convulxin) was reduced by 60%-70% compared with
WT controls. This defect in integrin activation also led to impaired
platelet aggregation in standard aggregometry (supplemental Fig-
ure 1). In the flow chamber assay, adhesion of CalDAG-GEFI	C1
platelets at venous (400 s1) and arterial shear rates (2000 s1) was
significantly increased compared with CalDAG-GEFI/ or WT/
clopidogrel platelets (Figure 7A-B). However, 3-dimensional
thrombi were only observed in CalDAG-GEFI	C1 blood perfused
under venous shear stress. To determine the pathophysiological
impact of reduced CalDAG-GEFI function, we evaluated the
bleeding time and the blood loss volume in CalDAG-GEFI	C1 mice
(Figure 7C). While the chimeric mice still bled for the entire observation
period, expression of CalDAG-GEFI	C1 limited the blood loss to
levels only slightly higher than those observed in WT chimeras. In
contrast, thrombus formation under flow (Figure 7A-B) and the
tail-bleeding time14 were normal in CalDAG-GEFI/ mice.
Figure 2. Laser-induced thrombosis in the cremaster muscle microcirculation. Mice were injected with Alexa488-labeled Fab fragments of MWReg30. (A,D) Changes in
fluorescence intensity over time measured after laser injury in cremaster muscle arterioles (A) or venules (D) of the following mouse groups: WT (black line), CalDAG-GEFI/
(KO, red), WT/clopidogrel (WT  clop., blue), CalDAG-GEFI/ / clopidogrel (KO  clop., green). Results represent the mean fluorescence intensity  SEM measured in 3
independent experiments (n  9-27 vessels for each group). Only significant differences (*P 
 .05; **P 
 .01; ***P 
 .001) are shown. (B,E) Representative images taken at
t  150” after laser injury in arterioles (B) and venules (E). See supplemental Videos 5-8 for a better visualization of the differences in thrombus growth and stability observed in
the respective study groups. Images were obtained on a Olympus BX61WI microscope (Olympus) with a 40/0.8 numeric aperture water-immersion objective lens, using
Slidebook software (Intelligent-Imaging-Systems). Dotted lines mark the vessel wall. White bar  100 m. (C,F) Number of emboli with a diameter of more than 10 m forming
after laser injury in arterioles (C) or venules (F) of WT, WT/clopidogrel, and CalDAG-GEFI/ mice. n  7-9. Mean venule diameter: WT: 63.4  8.5 m; WT  clopidogrel:
69.1  8.8 m; CalDAG-GEFI/: 55.9  6.1 m; CalDAG-GEFI/  clopidogrel: 60.2  4.2 m; P  nonsignificant (NS) for all comparisons. Mean arteriole diameter: WT:
37.3  3.0 m; WT  clopidogrel: 33.7  1.7 m; CalDAG-GEFI/: 38.1  2.5 m; CalDAG-GEFI/  clopidogrel: 37.1  1.9 m; P  NS for all comparisons.
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Discussion
The present study was based on our recent observations showing
that synergistic but independent signaling by CalDAG-GEFI and
P2Y12 leads to Rap1-dependent platelet activation. While both
pathways are able to induce Rap1 activation and platelet aggrega-
tion in vitro, we hypothesized that the different kinetics with which
they mediate Rap1 activation would translate to marked differences
in thrombus growth and stability in vivo. Our data demonstrate
delayed platelet adhesion and formation of thrombi in CalDAG-
GEFI–deficient mice compared with WT, confirming that CalDAG-
GEFI is crucial for the near-immediate activation of Rap1 and
IIb3 in circulating platelets (Figures 1-4). In agreement with this
observation, we also detected that thrombus formation in the
absence of CalDAG-GEFI was more prevalent in venules than in
arterioles (ie, under less stringent low shear conditions). In
contrast, thrombi in WT mice treated with clopidogrel formed with
similar kinetics to those in untreated WT mice, both in arterioles
and venules. Impaired P2Y12 signaling, however, led to frequent
embolization of growing thrombi, a phenotype that was not
observed in CalDAG-GEFI/ mice.
Our recent studies demonstrated that CalDAG-GEFI plays a
critical role for various aspects of platelet activation, including
integrin activation and the generation and release of autocrine
Figure 3. FeCl3-induced thrombosis in the mesentery. (A) Images of mesenteric venules taken 13 minutes after FeCl3 injury. Platelets were labeled by infusion of
fluorophore-labeled antibodies to platelet receptor GPIX. White bar  100 m. Dotted lines mark the vessel wall. Representative of 5 independent experiments. (B) Embolizing
thrombi in clopidogrel-treated WT animals stained positive for JON/A-PE, a probe that selectively detects the activated form of IIb3 integrin.23 Representative of 3
experiments. (C) Mean occlusion time in FeCl3-injured venules of mice of WT (solid black bar), WT/clopidogrel (WT  clop., solid white), and CalDAG-GEFI/ (KO,
checkered) mice (n  7-9). Note that none of the WT/clopidogrel or CalDAG-GEFI/ mice occluded within the 40 minutes observation period. (D) Average time required to
form a first thrombus of more than 20 m in diameter. (E) Number of emboli with a diameter of more than 20 m forming 8-13 minutes after FeCl3 injury. Mean venule diameter:
WT: 254.9  19.5 m; WT  clopidogrel: 305  28.7 m; CalDAG-GEFI/: 239  13.7 m; P  NS for all comparisons. All images were obtained on a Nikon Eclipse Ti-U
inverted microscope (Nikon) equipped with a Retiga EXL monochrome camera (QImaging) and the Nikon NIS Elements software (NIS-Elements Advanced Research).
Figure 4. FeCl3-induced thrombosis in the carotid artery. (A) Percentage of mice showing stable, unstable, or no thrombi in response to exposure of the carotid artery to
10% FeCl3 for 4 minutes (left) or 40% FeCl3 for 2.5 minutes (right). n  5 for all of the indicated study groups. (B) Flow traces recorded after exposure of the carotid artery of a
WT (WT, black line), WT  clopidogrel (WT  clop., gray line), or CalDAG-GEFl/ mouse (KO, dotted black line) to 40% FeCl3 for 2.5 minutes. Note the repeated changes in
blood flow in the clopidogrel-treated WT mouse, indicative of the generation of near-occlusive thrombi followed by embolization.
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mediators such as TxA2 and ADP.11,12,14 To evaluate if CalDAG-
GEFI/ mice are protected from thrombosis due to the defect in
the release of second wave mediators, we studied their adhesion in
the presence of exogenous ADP and TxA2. While addition of
exogenous mediators significantly increased the adhesion of
CalDAG-GEFI/ platelets to a collagen surface, particularly when
blood was perfused at venous shear rates, it did not restore growth
of 3-dimensional thrombi (Figure 1B-C). Thus, our data suggest
that the delayed kinetics of integrin activation rather than the defect
in the release of autocrine mediators is the main reason for the
marked antithrombotic phenotype of CalDAG-GEFI/ platelets.
We also observed significantly better hemostasis in CalDAG-
GEFI/ mice compared with clopidogrel-treated WT mice (Figure
5). While nearly all CalDAG-GEFI/ mice bled for the entire
observation period, 40% of these mice lost only marginally more
blood than WT controls. Both platelet-depleted and clopidogrel-
treated WT mice lost significantly more blood than CalDAG-
GEFI/ mice. It is likely that stable mural thrombi forming in
venules of CalDAG-GEFI/ mice support limited hemostasis.
Confirming this hypothesis, interventions that predominantly in-
hibit thrombosis under arterial shear conditions, such as inhibitors
of the GPIb–von Willebrand factor interaction, do not markedly
affect hemostasis in laboratory animals or humans.31-34
Based on these studies, we propose inhibition of CalDAG-GEFI
(or other molecules that are important for the first phase of IIb3
activation) as a new strategy for antiplatelet therapy. CalDAG-
GEFI plays a unique and critical role downstream of all agonist
receptors that stimulate the activation of phospholipase C. Thus,
inhibition of 1 molecule will affect multiple activation pathways.
Our studies in mice demonstrate that inhibition of CalDAG-GEFI
will provide better protection against thrombosis than inhibitors of
P2Y12, especially under arterial shear conditions such as found in
the setting of athero-thrombosis. We acknowledge the difficulty of
extrapolating results from mouse models of thrombosis to human
athero-thrombosis. However, we have used various microvascular
and macrovascular thrombosis models, which all demonstrated
virtually complete inhibition of arterial thrombosis in CalDAG-
GEFI/ mice. Clopidogrel treatment also protected mice against
the formation of occlusive thrombi. In concordance with previously
published results,10 it did not abolish thrombus growth but signifi-
cantly impaired thrombus stabilization. In fact, some of the fast
growing thrombi observed in WT/clopidogrel mice grew large
enough to affect blood flow in the injured carotid artery (Figure 4),
suggesting that similar near-occlusive events may occur on a
ruptured atherosclerotic plaque in clopidogrel-treated humans.
Thus, intervention in the first phase of Rap1-dependent integrin
activation, mediated by CalDAG-GEFI, may be superior to inhibi-
tion of sustained activation of Rap1/IIb3.
Its restricted expression profile is another favorable factor for
CalDAG-GEFI as a target for antiplatelet therapy. Compared with
other critical platelet signaling molecules such as phosphoinositide
3-kinase,35 Rap1,36 talin,37,38 or kindlin-3,39 which are abundantly
expressed in many cell types, CalDAG-GEFI is predominantly
expressed in platelets/megakaryocytes and neutrophils in the
hematopoietic system as well as certain neurons in the brain.13,14
Although CalDAG-GEFI is potentially important for motor con-
trol,40 no brain-related abnormalities have been reported for the
knockout mice. In our own studies, we showed impaired integrin
activation in neutrophils from CalDAG-GEFI/ mice,30 resulting
in protection of the mice in models of inflammatory disease.
Neutrophil extravasation, however, was only partially impaired in
CalDAG-GEFI/ mice, suggesting that an alternative pathway(s)
can support neutrophil integrin activation in the absence of
CalDAG-GEFI. Thus, CalDAG-GEFI inhibition may provide
strong antithrombotic protection without major side effects.
To prevent thrombosis yet minimize therapy-related bleeding
complications, partial inhibition of a critical player of platelet
Figure 5. CalDAG-GEFI–deficient mice show a similar bleeding time
but a reduced amount of blood loss compared with clopidogrel-
treated WT mice. (A) Tail-bleeding time in WT (circle, n  14), clopidogrel-
treated WT (WT  clop., triangle, n  20), CalDAG-GEFI/ (KO, square,
n  25), and platelet-depleted mice (WT plt. dep., diamond, n  10).
Three independent experiments. (B) Blood volume lost from the severed
tails. Each dot represents the bleeding time or blood loss volume
determined in individual mice.
Figure 6. Reduced integrin activation in platelets expressing CalDAG-
GEFIC1. (A) Representative flow cytometric analysis of the GFP expression in
platelets from chimeric mice expressing intact CalDAG-GEFI (WT/GFP, solid black
line) or CalDAG-GEFI	C1 (	C1/GFP, light gray shaded area) in comparison to WT
control platelets (dark gray shaded area). (B) Western blot analysis of CalDAG-GEFI
expression in CalDAG-GEFI/ (KO), WT, and CalDAG-GEFI	C1 (	C1) platelets.
Mutant CalDAG-GEFI was detected at a lower molecular weight due to the deletion of
the C1 domain (49 amino acids5.5 kDa). (C) Immunofluorescence staining for
CalDAG-GEFI in WT and CalDAG-GEFI	C1 (	C1) platelets. Results shown in
panels A-C are representative of 3 independent experiments. (D) IIb3 integrin
activation (JON/A-PE binding23) was determined in WT (solid bars), CalDAG-
GEFI/ (KO, checkered), CalDAG-GEFI	C1 (	C1, vertically striped), or CalDAG-
GEFI/ (HET, horizontally striped) platelets activated with PAR4 peptide (1mM,
top) or convulxin (Cvx, 750 ng/mL, bottom) in the presence of the P2Y12 inhibitor,
2-MesAMP. n  6, 3 independent experiments.
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activation may be required. In this study, we provide the first
evidence that targeting the regulatory C1 domain within CalDAG-
GEFI may be a unique means to reduce but not abolish its function,
independent of the dose of antagonist administered. Using a
retroviral approach,22 we generated chimeric mice expressing
CalDAG-GEFI	C1 in blood cells only (Figures 6-7). Deletion of
the C1 regulatory domain reduced CalDAG-GEFI–dependent
IIb3 activation by approximately 70%, resulting in significantly
impaired thrombus formation under low and high shear conditions.
In the tail bleed assay, mice expressing CalDAG-GEFI	C1 still
bled for the entire observation period, but the amount of blood loss
in all tested chimeras was only marginally higher than in WT
controls. In contrast, a 50% reduction in CalDAG-GEFI expression
did not affect platelet adhesion to collagen and hemostasis in mice.
This is the first report demonstrating an important role of the C1
domain for CalDAG-GEFI–mediated platelet activation. We cur-
rently do not know how the C1 domain contributes to CalDAG-
GEFI function. Previous studies in cell lines demonstrated that the
C1 domain in CalDAG-GEFI is atypical and thus binds DAG with
very low affinity.16,41,42 C1 domains, however, are also known as
protein interaction modules.43 Their binding partners include
adapter proteins such as 14-3-344 and Ras guanosine triphosphta-
ses,45 both of which are important in integrin inside-out activation.
Further studies are required to elucidate the underlying mechanisms.
In summary, our studies are the first to characterize how
differences in the kinetics of integrin activation, as observed in
CalDAG-GEFI/ or clopidogrel-treated WT mice, affect the
growth and stability of pathophysiological platelet-rich thrombi.
Based on these studies, we propose that targeting CalDAG-GEFI, a
critical player in the first phase of integrin activation, has the
potential to advance antiplatelet therapy in multiple ways. First,
CalDAG-GEFI inhibition will have an antithrombotic effect simi-
lar to or greater than that achieved with P2Y12 inhibitors like
clopidogrel but weaker than that of inhibitors of IIb3 integrin.
Second, the antithrombotic effect of CalDAG-GEFI inhibitors will
be more profound under arterial than venous shear conditions.
Third, CalDAG-GEFI–independent but P2Y12-dependent platelet
activation will allow for the formation of hemostatically active
thrombi in venules. Lastly, targeting one of the regulatory domains
within CalDAG-GEFI, such as the C1-like domain, will potentially
further improve the safety profile of such a new therapy.
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